These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 29271660

  • 1. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection.
    Maughan A, Ogbuagu O.
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):219-227. PubMed ID: 29271660
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
    Osinusi A, Bon D, Nelson A, Lee YJ, Poonia S, Shivakumar B, Cai SY, Wood B, Haagmans B, Lempicki R, Herrmann E, Sneller M, Polis M, Masur H, Kottilil S.
    J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150
    [Abstract] [Full Text] [Related]

  • 3. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Gluhovschi C, Gadalean F, Kaycsa A, Curescu M, Sporea I, Gluhovschi G, Petrica L, Velciov S, Bozdog G, Bob F, Vernic C, Cioca D.
    Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
    [Abstract] [Full Text] [Related]

  • 4. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S, Mehta M, Duseja A, Taneja S, Dhiman RK, Chawla Y.
    J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
    [Abstract] [Full Text] [Related]

  • 5. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M.
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [Abstract] [Full Text] [Related]

  • 6. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J, López-Cortés LF, Téllez F, Recio E, Ojeda-Burgos G, Ríos MJ, Rivero-Juárez A, Delgado M, Rivas-Jeremías, Pineda JA.
    PLoS One; 2015 Mar; 10(12):e0143492. PubMed ID: 26640956
    [Abstract] [Full Text] [Related]

  • 7. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M, Piattelli M, Annese M, Maio G, Conte D, Guadagnino V, Pazienza V, Festi D, Spirito F, Andriulli A.
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [Abstract] [Full Text] [Related]

  • 8. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B, Kovács B, Battyáni Z.
    Orv Hetil; 2011 Dec 11; 152(50):1997-2009. PubMed ID: 22112373
    [Abstract] [Full Text] [Related]

  • 9. Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.
    Pawlowska M.
    Expert Opin Drug Saf; 2015 Mar 11; 14(3):343-8. PubMed ID: 25599750
    [Abstract] [Full Text] [Related]

  • 10. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
    Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK.
    J Hepatol; 2010 Apr 11; 52(4):501-7. PubMed ID: 20189674
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study [KULDS] Group.
    J Gastroenterol Hepatol; 2012 Jul 11; 27(7):1233-40. PubMed ID: 22098185
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders.
    Poo JL, Sánchez Avila F, Kershenobich D, García Samper X, Torress-Ibarra R, Góngora J, Cano C, Parada M, Uribe M.
    Ann Hepatol; 2008 Jul 11; 7(4):369-75. PubMed ID: 19034238
    [Abstract] [Full Text] [Related]

  • 15. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
    Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM.
    Lancet; 2013 Jun 15; 381(9883):2100-7. PubMed ID: 23499440
    [Abstract] [Full Text] [Related]

  • 16. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM, ANRS HC27 BOCEPREVIH Study Group.
    HIV Clin Trials; 2016 Mar 15; 17(2):63-71. PubMed ID: 27077673
    [Abstract] [Full Text] [Related]

  • 17. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
    Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, Bonet L, Vidal F, Milinkovic A, Bassa A, Villalonga C, Pérez I, Tural C, Martínez-Rebollar M, Calvo M, Blanco JL, Martínez E, Sánchez-Tapias JM, Gatell JM, Mallolas J.
    Hepatology; 2009 Jan 15; 49(1):22-31. PubMed ID: 19085908
    [Abstract] [Full Text] [Related]

  • 18. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM.
    Gastroenterology; 2006 Oct 15; 131(4):1040-8. PubMed ID: 17030174
    [Abstract] [Full Text] [Related]

  • 19. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Slim J, Afridi MS.
    Infect Dis Clin North Am; 2012 Dec 15; 26(4):917-29. PubMed ID: 23083824
    [Abstract] [Full Text] [Related]

  • 20. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N, Besheer T, Gad Y, Elbendary A, Mokbel T, Abdel-Aziz A.
    J Ocul Pharmacol Ther; 2013 Apr 15; 29(3):345-8. PubMed ID: 23113644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.